Syndax Announces Data from Pivotal AUGMENT-101 Trial of Revu

Syndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual Meeting

Syndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual Meeting

lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

California , United States , San Diego , American , Michaela Metzger , Revumenib Monotherapy , Ibrahim Aldoss , Sharon Klahre , Data Monitoring Committee , American Society Of Hematology , Twitter , Linkedin , Prnewswire Syndax Pharmaceuticals Nasdaq , Syndax Pharmaceuticals , Exchange Commission , Syndax Pharmaceuticals Inc , Announces Data , Acute Leukemia Selected , Late Breaking Presentation , American Society , Annual Meeting , Chief Executive , Acute Leukemia , Topline Efficacy , Safety Results , Late Breaking Abstracts , Pivotal Phase , Independent Data Monitoring Committee , Oncology Review , Private Securities Litigation Reform Act ,